Shortly after the discovery of insulin, investigators reported that intravenous administration of this hormone leads to a transient hyperglycemia. Kimball and Murlin (1) suggested that this response was caused by the presence of a second physiologically active substance which they named glucagon. Some workers (2, 3) , however, suggested that this effect might be ascribed to insulin, or possibly to an artifact created during the manufacture of insulin (4) . Considerable evidence accumulated during the last decade favors the view that the short initial hyperglycemia observed following administration of insulin preparations, is due to the presence of small quantities of a second active substance, probably secreted by the a-cells of the pancreatic islets. The successful isolation of the hyperglycemic principle in highly purified and crystalline form (5) furnished conclusive proof that the factor is indeed an entity different from insulin. The amino acid composition of the crystalline material differs significantly from that of insulin (6) . Available evidence indicates that the two proteins also differ in regard to their physico-chemical properties.
Hence, it appears unlikely that difficulties in separating glucagon from insulin are due to similar chemical or physico-chemical properties as concluded by Burger and Brandt (7) . Although most of the hyperglycemic principle is removed from insulin in the course of its purification, small amounts can be found in most purified preparations. Many of these have been described as homogeneous on the basis of physico-chemical evidence (8) . However, more recent work, based on counter current distribution (9) , electrophoresis (10), and electrophoresis convection ( 11 ) , have suggested the presence of some heterogeneity in crystalline insulin preparations. Small amounts of glucagon might partly account for these findings. Several authors have attempted to estimate the glucagon content of various crystalline insulin preparations (10, (12) (13) (14) . These estimates, ranging from 1 to 10 per cent, have been obtained by indirect or at best semi-quantitative methods and must be regarded as tentative. The uncertainty of these results prompted the present quantitative study of the glucagon content of crystalline insulin samples. For this purpose the hyperglycemic activity of a number of different insulin preparations was compared with that of reference samples consisting of glucagon-free insulin to which known amounts of crystalline glucagon had been added. The results of these experiments are described in this paper.
BIOLOGICAL ASSAY
The method for measuring the biological activity of glucagon is based on the hyperglycemic response in cats (15) . This animal was selected because of its high sensitivity and comparatively constant response. Interference by the hypoglycemic action of insulin during the biological assay was prevented by incubating the samples with cysteine. This procedure destroys insulin activity but has no effect on the glucagon. Figure 1 shows the increase in blood sugar as a function of the glucagon dose. Experience has shown that greatest reproducibility is obtained in the range below half maximum response. For this reason the protein concentration of the test dose was adjusted so that the blood sugar rise was within the limits of 20 to 50 mg. per cent. Under these conditions maximum hyperglycemia occurs betweein 10 and 15 minutes following injection.
The standard deviations of column 3 in Table  II show that the net blood sugar increase, caused by a given dose of glucagon, varies within relatively wide limits. A typical example of the variation in sensitivity that may be expected is given in Table I .
Information about the sensitivity of each particular animal is gained by injecting a standard preparation of known potency immediately following the first 25-minute interval. Since the hyperglycemic peak again occurs between 10 and 15 minutes following injection, the second half of the test need not be extended beyond 15 minutes. Column 2 in Table I shows that the blood sugar rise caused by the standard varies approximately in proportion to the rise obtained by the sample injected initially. This makes it possible largely to eliminate the variable due to sensitivity Figure 2 . The slope of the straight line is a function of the potency of the standard preparation. The standard used in these experiments was equivalent to a solution of 4 mcg. of crystalline glucagon per ml.
EXPERIMENTAL PROCEDURE
A number of crystalline insulin preparations have been tested for their content of hyperglycemic factor.
Preparation of samples
Six mg. of crystalline Zn-insulin were dissolved in approximately 2 ml. of dilute acid and the pH was adjusted to 7.5 with 0.2 per cent sodium hydroxide. The volume was brought to 10 ml. after addition of 3.5 ml. of a one per cent cysteine solution of pH 7.5. The mixture was incubated for 16 hours at 18 to 23°C. This incubation period is sufficient to destroy most of the insulin activity.
The response ratios were determined as described above, injecting 0.05 ml. of incubated mixture per Kg. cat body weight. The protein concentration of the samples was adjusted so that the usual dose administered yielded a response ratio close to 0.8 or 1.6. These were the ratios obtained with similarly treated glucagonfree insulin preparations to which 0.3 and 0.6 per cent by weight of crystalline glucagon had been added. The glucagon-free insulin used for these experiments was a special preparation, to insulin in quantities up to 50 or 100 per cent by weight were without effect on the assay of insulin by either the mouse or the rabbit methods. Because of the short duration of the hyperglycemia caused by glucagon, its effect has disappeared before the insulin hypoglycemia was well established. Root (18) has found that administration of large amounts of highly purified glucagon over long periods to rats and rabbits does not cause any pathological changes. Furthermore, no permanent nor lasting alteration of the blood sugar level was observed. On the basis of these experiments it appears that glucagon has no significant influence on the hypoglycemic activity of insulin. Similarly there is no evidence that glucagon elicits undesirable side effects.
SUMMARY
The hyperglycemic factor content of some crystalline insulin samples has been determined on a quantitative basis. The crystalline Zn-insulin preparations contained 0.3 to 0.5 per cent of the factor. The effect of glucagon in insulin preparations is discussed.
